Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

31 Mar 2013

Abstract excerpt

The mechanisms underlying adaptive resistance of melanoma to targeted therapies remain unclear. By combining ChIP sequencing with microarray-based gene profiling, we determined that ERBB3 is upregulated by FOXD3, a transcription factor that promotes resistance to RAF inhibitors in melanoma. Enhanced ERBB3 signaling promoted resistance to RAF pathway inhibitors in cultured melanoma cell lines and in mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Immunotherapy and Immune Responses
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23543055
DOI: 10.1172/jci65780

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3PMID 23543055Read ↗

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.Semantic proximity Read ↗

Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling AxisSemantic proximity Read ↗

ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous MelanomaSemantic proximity Read ↗

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.Semantic proximity Read ↗

A growing family: adding mutated Erbb4 as a novel cancer target.Semantic proximity Read ↗

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.Semantic proximity Read ↗

ARRDC3 suppresses breast cancer progression by negatively regulating integrin β4Semantic proximity Read ↗

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsSemantic proximity Read ↗

FOXD3 Modulates Migration through Direct Transcriptional Repression of TWIST1 in MelanomaSemantic proximity Read ↗

Rnd3 Regulation of the Actin Cytoskeleton Promotes Melanoma Migration and Invasive Outgrowth in Three DimensionsSemantic proximity Read ↗

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.Semantic proximity Read ↗

Association of insulin-like growth factor binding protein-3 expression with melanoma progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.